<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529396</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 70177317.1.0000.0005</org_study_id>
    <nct_id>NCT03529396</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients</brief_title>
  <official_title>Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to assess the safety and efficacy of alternative regimens of primaquine for
      radical cure of vivax malaria in glucose 6-phosphate dehydrogenase (G6PD) deficient. G6PD
      deficient patients with P. vivax monoinfection will be treated with either weekly or delayed
      one-week course of primaquine, and the currently recommended by national guideline, 12-week
      chloroquine regimen to compare treatment safety among groups. All groups will be actively
      monitored for hemolysis during treatment and will have six-month follow-up period to assess
      treatment efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, phase II, clinical trial of safety and efficacy. Patients
      will be screened for eligibility and treated at the Fundação de Medicina Tropical Dr Heitor
      Vieira Dourado in Manaus, Brazil. A total of 60 vivax malaria patients will be recruited into
      the study, 30 G6PD deficient (Arm 1) and 30 G6PD normal (Arm 2). Patients with
      spectrophotometrically-confirmed G6PD deficiency (10-60% of adjusted mean male activity) will
      be divided into three subgroups of 10 patient each. All arms will receive standard 3-day
      chloroquine course. Additionally, Arm 1a will receive a delayed course of primaquine for 7
      days, starting only at the fifth-day post-chloroquine initiation. Arm 1b will receive weekly
      primaquine, once a week, for 8 weeks. Arm 1c will receive prophylactic 12-week course of
      chloroquine, as recommended by national guidelines for such patients (control group in terms
      of safety). Arm 2, the control group of efficacy, will receive standard regimen, comprised of
      3-day chloroquine plus concomitant 7-day primaquine. All patients will receive directly
      observed therapy (DOT) and will be closely monitored for clinical parameters and laboratory
      markers of hemolysis including hemoglobin, methemoglobin, lactate dehydrogenase, haptoglobin,
      reticulocytes, indirect bilirubin, aspartate aminotransferase, and urinalysis. All groups
      will be followed for 6 months after treatment to assess relapse rate. Primary endpoint is the
      tolerability of the regimens defined by hemoglobin fall. Secondary endpoints include
      treatment failure (relapse during follow-up), frequency of adverse effects, and rate of
      hemoglobin fall during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute or relative change in hemoglobin &lt; 3g/dL or 30% from baseline</measure>
    <time_frame>From date of randomization until the date of last dose, assessed up to 12 weeks.</time_frame>
    <description>Hemoglobin reduction from baseline after exposure to primaquine for P. vivax treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regimen efficacy</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Relapse rate over follow-up period after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>From date of randomization until the date of first documented event, assessed up to 12 weeks.</time_frame>
    <description>Presence of adverse reactions as a result of intervention, measured by clinical and laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin values over treatment</measure>
    <time_frame>through study completion: before intervention and up to 12 weeks during intervention.</time_frame>
    <description>Absolute variation of hemoglobin levels before and during intervention.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vivax Malaria</condition>
  <condition>G6PD Deficiency</condition>
  <arm_group>
    <arm_group_label>1a: Chloroquine + 5th-day Primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten G6PD deficient patients. Directly observed therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b: Chloroquine + 8-week Primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten G6PD deficient patients. Directly observed therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1c: Chloroquine + 12-week Chloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ten G6PD deficient patients. Control group in terms of safety. Directly observed therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Standard chloroquine + primaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Standard chloroquine (three days)</description>
    <arm_group_label>1a: Chloroquine + 5th-day Primaquine</arm_group_label>
    <arm_group_label>1b: Chloroquine + 8-week Primaquine</arm_group_label>
    <arm_group_label>1c: Chloroquine + 12-week Chloroquine</arm_group_label>
    <arm_group_label>2: Standard chloroquine + primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.</description>
    <arm_group_label>1a: Chloroquine + 5th-day Primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.</description>
    <arm_group_label>1b: Chloroquine + 8-week Primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)</description>
    <arm_group_label>1c: Chloroquine + 12-week Chloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.</description>
    <arm_group_label>2: Standard chloroquine + primaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncomplicated vivax malaria monoinfection

          -  G6PD deficiency ranging from 10%-60% of adjusted mean male activity

          -  Baseline hemoglobin &gt;9 g/dL

          -  Willing to comply with study requirements

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Comorbidities (hepatopathy and/or nephropathy)

          -  Use of antimalarials in the previous two weeks or current use of potentially hemolytic
             drugs

          -  Any condition which would place the subject at undue risk of hemolysis or interfere
             with the results of the study, as judged by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus VG Lacerda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fiocruz/ILMD and Fundacao de Medicina Tropical Dr Heitor Vieira Dourado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wuelton M Monteiro, PhD</last_name>
    <phone>+55 (92) 99165 2486</phone>
    <email>wueltonmm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose Diego B Sousa, BSc</last_name>
    <phone>+55 (92) 99166-9617</phone>
    <email>sousajdb@live.com</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</investigator_affiliation>
    <investigator_full_name>Wuelton Marcelo Monteiro, PhD</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>G6PD deficiency</keyword>
  <keyword>Acute hemolytic anemia</keyword>
  <keyword>Vivax malaria</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Weekly primaquine</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Weekly chloroquine</keyword>
  <keyword>Brazilian Amazon</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

